Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5771064

O=C(CCc1cnoc1-c1ccc(F)cc1)Nc1ccncc1.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
MAPK14 Q16539 3/20 0.43
BCHE P06276 1/20 0.41
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
CNR2 P34972 1/20 0.38
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPY5R Q15761 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5771101 0.92 TP53 (0.46) LMNABCHEMAPTMEN1KMT2A
SCHEMBL5773332 0.86 CNR2 (0.51) LMNAMAPK14MAPTMEN1KMT2A
Trifluoroacetic Acid SCHEMBL5771828 0.86 GSK3B (0.42) LMNAMAPK14MAPTKMT2ASMN1; SMN2
SCHEMBL5777386 0.86 LMNA (0.47) LMNAMAPK14MAPTMEN1KMT2A
Trifluoroacetic Acid SCHEMBL5773568 0.85 EPHX2 (0.52) MAPK14MEN1KMT2ATAAR1TP53
Trifluoroacetic Acid SCHEMBL5772665 0.82 NPC1 (0.52) LMNAMAPTTP53SMN1; SMN2HDAC4
Trifluoroacetic Acid SCHEMBL5775470 0.82 CNR2 (0.52) MAPTMEN1KMT2ACNR2HDAC3
Trifluoroacetic Acid SCHEMBL5770756 0.82 HDAC6 (0.42) MAPTMEN1KMT2ACNR2HDAC3
SCHEMBL5773606 0.81 MAPT (0.48) LMNAMAPTMEN1KMT2ACNR2
SCHEMBL5771183 0.80 ROCK2 (0.45) LMNAMAPK14MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060084690-A1 Isoxazole derivatives MOMOSE YU 2006-04-20 US disclosed
US-7022725-B2 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-04 US disclosed
US-20040048908-A1 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-11 US disclosed
EP-1340749-A1 ISOXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084690-A1 Isoxazole derivatives INSR, GPR119, INSRR LMNA 2770/4885MAPK14 1376/4885BCHE 1810/4885
US-20040048908-A1 Isoxazole derivatives GPR119, INSR, IRS1 LMNA 2605/4885MAPK14 1203/4885BCHE 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.